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Abstract
Background:  The R122H mutation of the cationic trypsinogen was found in patients with
hereditary pancreatitis. A transgenic animal carrying this mutation could be useful as a genetic
model system of pancreatitis.
Methods: Mice transgenic for the human R122H cationic trypsinogen were generated using the -
205 fragment of the rat elastase promoter. The presence of the transgene was assayed in the DNA,
in pancreatic mRNA and in zymogen granule lysates. Serum levels of amylase, lipase and cytokines
(MCP-1, IL-6) were monitored and the histological appearance of the tissue was investigated.
Pancreatitis was induced by 7 hourly injections of 50 µg/kg cerulein. The procedure was repeated
twice weekly for 10 consecutive weeks. The animals were sacrificed 24 (n = 8) and 48 hours (n =
8) after the first injection and at the end of the whole treatment (n = 7).
Results:  The transgene was detected at the genomic level and in pancreatic mRNA. The
corresponding protein was found in low amounts in zymogen granule lysates. R122H mice showed
elevated pancreatic lipase, but there was no spontaneous development of pancreatitis within 18
months. After induction of pancreatitis, levels of lipase (after 24 hours) and amylase (after 48 hours)
were higher in R122H mice compared to controls. Repeated treatment with cerulein resulted in a
slightly more severe pancreatitis in R122H animals. Amylase, lipase, and the cytokine levels were
similar to controls.
Conclusion: The R122H transgenic mouse failed to develop a spontaneous pancreatitis but a
repeatedly provoked cerulein-induced pancreatitis led to a slightly more severe pancreatitis. The
rather small difference in comparison to controls could be due to the low expression of the
transgene in the mouse pancreas.
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Background
The exact mechanism of acute pancreatitis is still
unknown. A widely accepted theory is that pancreatitis
develops due to activation of pancreatic enzymes leading
to autodigestion of pancreatic tissue and inflammation
[1]. Secondary damages of cell membranes, edema, and
vascular alterations followed by hemorrhage and necrosis
are completing the clinical picture. Most likely, the central
step in the pathogenesis is the activation of trypsinogen to
trypsin which most probably occurs intracellularly. As it is
unclear in what cellular compartment this takes place, sev-
eral pathways may be involved like trypsinogen autoacti-
vation, trypsin activation by the lysosomal hydrolase
cathepsin B, or reduced content or activity of the secretory
trypsin inhibitor [2-4].
The important role of trypsin in pancreatitis was under-
lined by the discovery of mutations of the cationic
trypsinogen in hereditary pancreatitis [5-8], a disease with
an autosomal dominant pattern of inheritance [9,10].
Clinical characterization showed an onset of disease in
early childhood, but the further progression of hereditary
chronic pancreatitis was found to be slower than in the
alcoholic form [11]. According to biochemical data
obtained from investigation of recombinant enzymes
expressed in bacteria, almost all different analysed muta-
tions of the cationic trypsinogen led to a gain of function
of the molecule [12]. But apart from in-vitro data, the cel-
lular effects of expression of the mutated trypsins were not
yet investigated.
In a recent study we showed a higher rate of apoptosis
after expression of R122H trypsinogen in the cell line
AR4-2J [13]. These results suggested that transgenic mice
carrying the R122H mutation could serve as a model for
pancreatitis. In this paper we describe the generation of
such an animal, characterize its phenotype and show that
after repeated cerulein injections a slightly more severe
pancreatitis was found than in normal mice.
Methods
Construction of the targeting vector
The cDNA of human cationic trypsinogen was amplified
from the pTry vector [13] by PCR using the primers 5'Try-
lang BamHI (ccg gga tcc tca ggc aca ctc tac cac cat gaa tcc
act cct gat cct tac c) and 3'Try-BamHI (ccc gga tcc gct tta gct
att ggc agc tat gg). PCR conditions were 5 min at 94°C, 35
cycles of 10 sec at 94°C, 30 sec at 60°C and 1 min at 72°C
using the Expand High Fidelity polymerase (Roche Diag-
nostics, Mannheim, Germany). The PCR product was sub-
cloned into the pGEMeasy (Promega, Mannheim,
Germany) vector. After digestion with BamHI the cDNA
was subcloned into the pUC119 vector carrying rat
elastase-II enhancer/promotor region, -500/+8EI(Bam
del), a generous gift from Galvin Swift, University of
Texas. Correct orientation of the cDNA behind the
elastase promotor was proven by appropriate restriction
digestion. A PCR product called Ela-Try spanning the -205
to +8 region of the elastase promotor and the cDNA of
human cationic tryposinogen was amplified with the
primers Ela-205-NruI (ggg tcg cga gtc gac ttg ggt taa ctg agt
gc) and 3'Try-HindIII (ccc aag ctt gct tta gct att ggc agc tat
gg). The pcDNA3 vector (Invitrogene, Karlsruhe, Ger-
many) was cut by NruI and HindIII to eliminate the CMV
promotor. The ElaTry fragment was digested with NruI
and HindIII and subcloned into pcDNA3. The R122H
mutation and a second MfeI side on the backbone vector
were introduced by site directed mutagenesis using stand-
ard techniques (Quickchange Stratagene, Cedar Creek, TE,
US). The respective primers were R122H-upstream (acg
tgc agt aat caa cgc cca cgt gtc c) and R122H-downstream
(cag aga gat ggt gga cac gtg ggc gtt g) as well as MfeI-sense
(tga ccg cta caa ttg cca gcg c) and Mfe1-antisense (g cgc tgg
caa ttg tag cgg tc). The whole construct was verified by
double strand sequencing. The MfeI digested product
comprising the -205 to 8+ region of the elastase promotor,
R122H trypsinogen cDNA and the bovine growth hor-
mon (bGH) polyadenylation signal was used as the target-
ing sequence (see figure 1).
Generation and characterisation of the transgenic line
Transgenic animals were generated by standard tech-
niques using a commercial provider (mice and more/
Hamburg, Germany). We obtained one male founder ani-
mal. Transgenic animals were backcrossed onto a BalbC
background. Principles of laboratory animal care were fol-
lowed, and the type of study was approved by the local
ethic committee.
Verification of the transgene on genomic, mRNA and 
protein level
Genomic DNA from mice was prepared from tail tips
using standard procedures (DNeasy Tissue Kit, Qiagen,
Hilden, Germany). Presence of the transgene was proven
by PCR spanning the elastase promoter, the cDNA of
R122H trypsinogen and the bGH-polyadenylation signal
using the primers NruI-Ela (gct tcg cga gtc gac ttg g) and
Poly-rev (Cag cat gcc tgc tat tgt c) under standard condi-
tions (see figure 1 for schematic position of the primers).
A primer pair (ConForw: ctg gac tct gac atg tgc aca tac;
ConRev: cta cat gca gga tga cca gca tag) complementary for
Connexin 31 was used as a control (data not shown).
Total RNA from mouse pancreas was prepared after
homogenization of the pancreatic tissue using the RNeasy
Protect Mini Kit (Qiagen, Hilden, Germany). 5 µg of total
RNA was reverse transcribed with SuperScript II Kit (Invit-
rogene, Carlsbad, CA, US) following the recommenda-
tions of the supplier. The trypsinogen-specific PCR
conditions for cDNA amplification were 94°C for 5 min.,BMC Gastroenterology 2006, 6:30 http://www.biomedcentral.com/1471-230X/6/30
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a. Schematic illustration of the targeting vector Figure 1
a. Schematic illustration of the targeting vector: The vector is carrying the minus-205 fragment of the rat elastase pro-
motor, the Kozak consensus, the cDNA of human cationic trypsinogen with the R122H mutation, and the bGH-polyadenyla-
tion signal of the bovine growth hormone. The position of the PCR primer for the verification of the transgene on genomic and 
on mRNA levels (NruI-Ela and Poly-rev) as well as the controls are indicated (TG-forward, TG-reverse, TryUp) b. Verifica-
tion of the transgene in genomic DNA: Lane 1: 1000 bp marker, lane 2: 100 bp marker. Genomic DNA from transgene 
animals (lane 4–6), positive control (targeting vector diluted 1:10 000, lane 3), and negative control (water, lane 7) were used 
as a template with primers spanning the elastase promoter, the cDNA of human cationic trypsinogen, and the polyadenylation 
signal of the bovine growth hormone (NruI-Ela and Poly-rev). The PCR resulted in a single band of the expected size of 1352 
bp. c. Verification of transgene on mRNA level: After mRNA preparation from pancreatic tissue a reverse transcription 
PCR was performed with either two upstream primers complementary to cationic trypsinogen (pTry) (used in lane 3, 4, 6) or 
to the elastase promotor (TG-forward) as a control. The downstream primer was complementary to trypsinogen (TG-
reverse) (used in lane 5 and 7). Position of the primers see figure 1a. lane 1: 1000 bp marker, lane 2: 100 bp marker, lane 3: 
water control, lane 4: cDNA from a transgenic animal; PCR product with the expected size of 409 bp, lane 5: cDNA from a 
transgenic animal; no PCR product, lane 6: positive control for lane 4: targeting vector diluted 1:10 000, lane 7: positive control 
for lane 5: targeting vector diluted 1:10 000. d. Verification of the transgenic protein: Zymogene preparation from mouse 
pancreata or pancreatic juice were subjected to isoelectric focussing followed by western blot using a antibody directed against 
human cationic trypsinogen (lane 1: pancreatic juice; lane 2–5: control animals; lane 6: transgenic animal)
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35 cycles of 30 sec at 94°C for 30 sec., 55°C for 30 sec.
and 72°C for 90 sec. followed by 5 min at 72°C using
Ampli Taq DNA Polymerase (Roche) and the primers
TryUp (act gtg agg aga att ctg tcc) and TG-reverse (ctt cac
act tag cct ggc tca gc). The PCR product was sequenced by
standard procedures by a commercial provider (AGOWA,
Berlin, Germany). To exclude DNA contaminations, the
primer pair TG-forward (tca gca gag ctg ctg ata aga gc) and
TG-reverse was used with the upstream primer being com-
plementary to a sequence in the rat elastase promoter (see
figure 1a for schematic position of the primers).
To detect the transgenic protein, zymogen granules were
isolated from mouse pancreas [14]. The pancreata were
rinsed in chilled 280 mM sucrose solution, homogenized
mechanically, and centrifuged for 10 min at 4°C with 600
g. The supernatants were transferred to a new tube and
centrifuged for 10 min at 4°C with 1100 g. The obtained
pellets were washed 3 times with 1 ml washing buffer (5
mM MES, 280 mM sucrose, pH 6) carefully to remove the
brown layer from the white zymogen granules pellet. This
pellet was resolved in 150 µl washing buffer and 75 µl
lysis buffer (170 mM sodium chloride, 200 mM
NaHCO3, 0,02% TritonX-100, pH 7,8) and incubated for
2 hours on ice. After centrifugation for 45 min at 4°C at
12.000 g the pellet was stored at -80°C. All solutions were
supplemented with complete Mini-EDTA-free Proteinase
Inhibitor Tabs (Roche Diagnostics, Mannheim, Ger-
many).
Protein preparations were separated by isoelectric focuss-
ing employing fixed gradient gels (SERVAlyt Prenets pH
3–10, Electrophoresis GmbH, Heidelberg, Germany) and
a focussing chamber (Amersham Bioscience, Bucking-
hamshire, UK). The proteins were separated at 2000 V/h,
11 W and 8 mA at 4°C for 3 hours and then transferred to
nitrocellulose membranes for western blotting. The mem-
branes were incubated with a rabbit antibody (diluted
1:2000 in 0,1% Tween-PBS) directed against human
trypsin (Paesel&Lorei, Duisburg, Germany). The second
antibody used was a peroxidase-labelled anti-rabbit-Ig
and the bands were visualized by autoradiography using
the ECL-system (Amersham Bioscience, Braunschweig,
Germany).
Induction of experimental pancreatitis
To follow the spontaneous development of pancreatitis,
pancreatic tissue specimen were taken at an age of 8, 12
and 18 months. For all other experiments, mice of an age
of 8 months were used. A transgenic and control group,
four mice each, were fed a protein rich diet for 6 weeks in
order to stimulate trypsin synthesis by the pancreas. In all
other animals, a standard lab chow was given. The mice
were sacrificed by cervical dislocation after CO2 anaesthe-
sia.
Acute experimental pancreatitis was induced by intraperi-
toneal cerulein injections (50 µg cerulein/kg body weight,
7 times in hourly intervalls) in transgenic mice and con-
trol BalbC mice at the age of 8 months (9 mice each group
and time). Animals were sacrified 8, 24, and 48 hours
after first injection and the pancreas was removed for his-
topathology. Serum was taken to determine enzymes and
cytokine levels as described above. To induce a recurrent
pancreatitis repeated cerulein injections were performed
in 8 month-old transgenic and control mice (n = 8 each).
The animals received 7 hourly injections of cerulein (50
µg per kg body weight) two times per week over a 10-week
period according to a recent protocol [15]. Three days
after the last injection the animals were sacrificed, and
serum was recovered and the pancreatic gland was proc-
essed for histopathology.
Determination of serum markers
Serum lipase, amylase, ALAT, ASAT, alkaline phosphatase
and glucose (Modular, Roche Diagnostics, Mannheim,
Germany) were measured in blood samples taken from
the retrobulbar plexus. The cytokines MCP-1, IL6, IL10,
IL12p70, TNF and IFN-gamma were determined in dupli-
cates by a multiplex fluorescent bead immunoassay (cyto-
metric bead array, CBA Mouse Inflammation Kit, Becton
Dickinson, San Jose, CA, USA) using a flow cytometer
(FACS Calibur™, Becton Dickinson).
Histopathological analysis
From all animals pancreatic tissue samples were fixed in
10% formalin, embedded in paraffin, sectioned, mounted
on a slide and stained with H&E for microscopic examina-
tion. The severity of the cerulein-induced inflammation
was graded using a scoring system (a scale of 0–3 (0 being
normal and 3 being severe)) [16]. A score from 0 to 3 was
ascribed to each of the following qualifiers: (a) the extent
of the edematous reaction, (b) the number of infiltrating
granulocytes and macrophages, (c) vacuolization of aci-
nar cells, and (d) the presence of apoptotic acinar cells.
The scores of the three qualifiers were added to obtain a
total score. A score of 1–2 was considered grade I inflam-
mation, a score of 3–5 grade II and a score of 6–9 grade III.
Statistics
Statistical analysis was performed using the Mann-Whit-
ney test.
Results
Verification of the transgene on genomic, transcriptional 
and protein level
The human R122H cationic trypsinogen in the transgenic
mice was verified by a PCR spanning the elastase pro-
moter, the cDNA of human cationic trypsinogen, and the
bGH-polyadenylation signal (figure 1b) showing a single
band of the expected size of 1352 bp.BMC Gastroenterology 2006, 6:30 http://www.biomedcentral.com/1471-230X/6/30
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After preparation of mRNA from mouse pancreas the
transgene was detected by rtPCR (figure 1c: lane 4). The
PCR product was sequenced in both directions to verify
the human cationic trypsinogen as well as the R122H
mutation (data not shown). To rule out contamination
with genomic DNA in our cDNA preparation we used
primers specific for the targeting sequence (spanning the
elastase promotor and the cDNA of human cationic
trypsinogen) (figure. 1c: lane 5). Diluted targeting vector
served as a control for this PCR (figure. 1c: lane 7).
To identify the human cationic trypsinogen protein in the
mouse pancreas, zymogen granules were prepared, the
proteins were separated by isoelectric focussing, trans-
ferred on nitrocellulose membranes and incubated with
an antibody towards human trypsinogen. In controls as
well as in transgenic animals the antibody labeled several
immunoreactive protein bands (figure 1d: lanes 2–6). A
single cationic trypsinogen and a group of anionic
trypsinogens were identified that corresponded to the
known isoelectric points of the mouse cationic (pI 8.0)
and anionic trypsinogens (pI 4.3–5.4). As a control, we
also separated a sample of human pancreatic juice (figure.
1d: lane 1) [17]. In the pancreatic juice the antibody
detected two bands corresponding to cationic tryosinogen
(pI 6,1 calculated with the "ProtPram" tool [18] and ani-
onic trypsinogen (pI 4,8). At the same position we found
an additional band in the pancreatic zymogen prepara-
tion of the transgenic mice in the western blot after isoe-
lectric focussing (figure. 1d: lane 6) but not in controls
(figure. 1d: lane 2–5). This band corresponded to the tran-
genic R122H trypsinogen which theoretical pI being 6,0.
The theoretical pI of cationic trypsinogen is only slightly
different to the pI of human cationic trypsinogen (6.4)
determined by 2-dimensional gel electrophoresis [19].
Phenotype of the transgenic animals
No spontaneous alteration of pancreatic histology was
found in mice at 8 (figure 4a and 4b), 12 and 18 months
(six per group) of age (data not shown). Similarly, the his-
tological appearance of pancreas specimen was also unal-
tered after feeding a protein rich chow (data not shown).
However, at an age of 8 months transgenic mice displayed
significantly elevated levels of serum lipase, but not of
amylase (figure 2a and 2b).
Phenotype after induction of experimental pancreatitis
After induction of pancreatitis with cerulein, amylase (fig-
ure. 3a), lipase (figure 3b) as well as the cytokines MCP-1
and IL-6 (table 1) raised with maximal values after 8
hours. Compared to controls, lipase (after 24 hours) and
amylase (after 48 hours), but not IL-6 and MCP-1 levels
were significantly elevated in R122H animals (table 1).
Serum values for ALAT, ASAT, alkaline phosphatase and
glucose (data not shown) and the cytokines IL-10, IL-
12p70, TNF and IFN-gamma did not change significantly
(table 1). Histologically, the pancreas showed an intersti-
tial edema and a scarce infiltration with neutrophil gran-
ulocytes and macrophages. There were no differences
between transgenic animals and controls (table 2).
After repetitive intraperitoneal cerulein injections, pancre-
atitis was more severe in R122H transgenic animals than
in controls. Transgenic mice had a denser interstitial infil-
trate consisting of granulocytes and macrophages (figure
4). The pancreatic tissue showed a more acinar dilatation
Basal serum levels of amylase and lipase in R122H-trypsinogen transgenic mice and controls Figure 2
Basal serum levels of amylase and lipase in R122H-trypsinogen transgenic mice and controls: Serum levels of 
amylase (a) and lipase (b) were measured in a minimum of 10 animals per group (R122H transgenic mice: grey, wild-type mice: 
white). Statistical analysis using the Mann-Whitney-Test with p < 0.05 was considered significant.
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and apoptotic acinar cells. Using a quantitative scoring
system that estimated the degree of inflammatory reac-
tion, number of infiltration granulocytes and macro-
phages and the presence of apoptotic or necrotic acinar
cells we found a significantly more severe damage of the
pancreas in the R122H mice (figure 4).
Discussion
The description of genetically determined forms of
chronic pancreatitis has fleshed out the hypothesis of the
central role of trypsin activation in the pathogenesis of
pancreatitis. Cationic trypsinogen (PRSS1) mutations are
associated with hereditary pancreatitis, an autosomal
dominant disease [7]. Biochemical data show that the two
most common mutations of cationic trypsinogen
(R122H, N29I) associated with hereditary pancreatitis
lead to enhanced trypsin activity [20,21]. On the other
hand, a loss of function mutation of anionic trypsinogen
(PRSS2) protects against chronic pancreatitis [22]. Muta-
tions of SPINK1, the main intraacinar trypsin inhibitor,
are associated to idiopathic [23], alcolholic [24] and the
tropical form [25] of chronic pancreatitis. These findings
in genetically determined forms of chronic pancreatitis
indicate that an imbalance between trypsin activity and
trypsin inhibition in favour of enhanced proteolytic activ-
ity is the central pathogenetic factor in pancreatitis.
Several different mutations of cationic trypsinogen were
found in patients with autosomal-dominant pancreatitis
[26]. The R122H mutation of this enzyme is the most fre-
quent one and it is reasonable to assume that transgenic
expression of this protease in animals could serve as an
experimental model for pancreatitis. To date such a con-
struct was not available and this encouraged us to generate
a transgenic mouse expressing R122H human cationic
trypsinogen. The -205 fragment of the rat elastase pro-
moter (figure 1) was chosen since this fragment was
shown to give a strong transgenic expression in murine
exocrine pancreas [27].
We detected the transgene at the genomic level by PCR
with primers specific for the targeting sequence (figure
1b). The expression of the corresponding messenger RNA
was confirmed by rtPCR (figure 1c). To detect the R122H
trypsinogen at the protein level, zymogen granules were
separated by isoelectric focussing. After labeling with anti-
bodies against human trypsin there was a substantial
number of immunoreactive bands both in the wild type as
well as in the transgenic animals (figure 1d). These repre-
sent the different murine forms of the trypsins that were
present in the mouse pancreas. The additional band iden-
tified in the transgenic mice was comparatively weak and
exhibited an isoelectric point of approximately 6.0. The
band was found at the same isoelectric point as cationic
trypsinogen from human pancreatic juice (figure. 1d).
This indicates that the additional band represents the
transgenic human R122H cationic trypsinogen. Taking
into account the lower density of the band of the trans-
genic protein and the higher affinity of the antibody
against the human protein, we achieved only a rather low
expression of the human proenzyme compared to the
endogenous murine trypsinogens.
Serum levels of amylase and lipase during experimental pancreatitis in R122H-trypsinogen transgenic mice and controls Figure 3
Serum levels of amylase and lipase during experimental pancreatitis in R122H-trypsinogen transgenic mice 
and controls: After induction of experimental pancreatitis serum levels of amylase (a) and lipase (b) were measured at time 
points 0, 8, 24, and 48 hours (see materials and methods) in a minimum of 4 animals per group (R122H transgenic mice: black 
triangels, wild-type mice: white triangels). Statistical analysis using the Mann-Whitney-Test with p < 0.05 was considered signif-
icant.
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Histological evaluation after repeated induction of pancreatitis in transgenic mice and controls Figure 4
Histological evaluation after repeated induction of pancreatitis in transgenic mice and controls: R122H trans-
genic animals and controls were sacrificed without treatment (a, b) or after repetitive induction of experimental pancreatitis (c, 
d) R122H transgenic mice (grey) and controls (white) were left untreated or were treated with repetitive inductions of pancre-
atitis in a minimum of 7 animals per group. Pancreata of the animals were histologically evaluated for the grade of diffuse infil-
tration (e). R122H transgenic mice (d) showed significantly higher grade of diffuse inflammatory infiltration than control animals 
(c). Statistical analysis using the Mann-Whitney-Test with p < 0.05 was considered significant.
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We investigated whether the mice spontaneously develop
acute or chronic pancreatitis. Within the normal lifetime
of 18 months, however, the pancreas remained normal in
all transgenic animals. Furthermore, increasing the trypsin
content by feeding a protein rich diet did not alter the his-
tological findings (data not shown). We did not detect any
baseline differences in the histology of pancreata from
transgenic animals and controls. However, the slightly
higher serum levels of lipase and amylase (figure 2) sug-
gests a subtle acinar damage that is not reflected by histo-
logical changes.
To promote the development of pancreatic disease in the
mice, an acute pancreatitis was induced by intraperitoneal
injection of cerulein. The initial acute phase reaction
(increase of serum amylase and lipase (figure 3a and 3b)
and cytokines MCP-1 and IL-6 (table 1) was similar in
R122H mice and controls. However, in the later course of
the disease the enzyme levels remained significantly
higher in the transgenic animals (figure 3a and 3b). Again,
there were no differences in the histological pancreatitis
score between the two groups of mice (table 2).
Programmed cell death was supposed to play a crucial role
in the pathogenesis of pancreatitis [28]. We observed
induction of apoptosis by expression of mutated trypsino-
gens in the acinar cell line AR4-2J [13]. In contrast, after
induction of experimental pancreatitis we did not detect a
higher grade of apoptosis in R122H-trypsinogen trans-
genic mice compared to control (table 2). This difference
might be due to the fact that in pancreatic acinar cells of
mice higher expression level of trypsin inhibitors (PSTI/
SPINK1) or other protective mechanisms hinder the pro-
apoptotic effect of intracellular activated trypsin.
Pancreatic enzyme levels in transgenic animals remained
elevated after 24 or 48 hours (figure 3) suggesting that the
transgenic protein prolong the time until the pancreas
fully recovers from the inflammation. To test this hypoth-
esis, we treated the animals with repetitive intraperitoneal
cerulein injections [15,29]. After this long-term challenge
there were no differences in serum enzymes and cytokine
levels, but a significantly higher severity of interstitial
inflammation in the pancreas of transgenic mice (figure.
4e). This finding indicates that the expression of the
R122H cationic trypsinogen gene could slightly aggravate
the disease under these conditions.
The most likely reason for the small differences between
transgenic animals and controls is the low expression of
the transgenic protein. Using an in-vitro system to observe
the biological effect of expression of mutated trypsinogen,
we observed that R122H trypsinogen leads to cell death
by enhanced intracellular trypsin activity [13]. We specu-
late that higher amounts of R122H cationic trypsinogen
probably provoke a spontaneous phenotype in mouse.
Therefore, the development of mice expressing higher lev-
els of mutated trypsinogen may offer the opportunity to
replicate the human disease.
Table 1: Serum cytokine levels during induction of experimental pancreatitis in R122H-trypsinogen transgenic mice and controls:
untreated 8 h 24 h 48 h
cytokines (pg/ml) R122H control R122H control R122H control R122H control
MCP-1 mean ND ND 242,0 279,0 137,0 84,0 75,0 72,0
SD 137,0 91,0 77,0 26,0 42,0 30,0
Il-6 mean ND ND 60,0 74,0 6,0 9,0 6,0 4,0
SD 56,0 76,0 3,0 17,0 6,0 3,0
Il-10 mean ND ND 5,0 6,0 3,0 2,0 4,0 2,0
SD 2,0 5,0 1,0 0,0 4,0 0,0
Il-12p70 mean ND ND 15,0 18,0 7,0 15,0 8,0 20,0
SD 11,0 13,0 1,0 16,0 5,0 16,0
TNF mean ND ND 10,0 10,0 8,0 5,0 9,0 7,0
SD 1,0 2,0 1,0 3,0 5,0 3,0
IFN-γ mean ND ND 0,5 0,5 0,5 0,5 0,5 0,5
SD 0,0 0,0 0,0 0,0 0,0 0,0
Results are expressed as means and standard deviation (n = 10). ND = detectable. There were no significant differences between transgenic animals 
and controls.
Table 2: Histological score during induction of acute 
experimental pancreatitis in R122H-trypsinogen transgenic mice 
and controls:
edema infiltration vacuolization apoptosis
control mean 1,6 1,0 1,4 1,0
SD 1,0 0,7 1,1 0,7
R122H mean 1,7 1,1 1,3 1,1
SD 0.9 0,9 1,0 0,9
Results are expressed as means and standard deviation (n = 10). There 
were no significant differences between transgenic animals and 
controls.BMC Gastroenterology 2006, 6:30 http://www.biomedcentral.com/1471-230X/6/30
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Interestingly, there are two conflicting reports about
genetically engineered mice of the opponent of active
trypsin in pancreas, the serine protease inhibitor Kazal typ
1 (SPINK1), also called pancreatic sectreted trypsin inhib-
itor (PSTI). Transgenic expression of rat PSTI-I in mouse
ameliorates secretagogues induced pancreatitis [30]. In
this mouse model, in accordance with our hypothesis,
inhibition of active trypsin is the reason for the protective
effect of PSTI. The other study showed that targeted dis-
ruption of the mouse homologue of human SPINK1,
murine SPINK3, is lethal at day 14,5 after birth [31]. The
reason was a rapid onset of cell death in pancreas and
duodenum a few day after birth. In Spink3-/- mice, the
pancreas developed normally up to 15.5 days after con-
ception. However, the authors did not find enhanced
trypsin activity in the developing pancreas in the absence
of SPINK3. These conflicting data [30,31] indicate that
additional studies and animal models are warranted to
understand the function of the trypsin inhibitior SPINK1/
PSTI in the pathogenesis of pancreatitis. Analogical, our
paper will probably open the discussion on the effect of
mutated trypsinogen in pancreatic acinar cells since there
are to our knowledge several other groups also developing
transgenic animals which express mutated trypsinogen.
Conclusion
In summary, we generated transgenic mice expressing low
amounts of R122H mutated human cationic trypsinogen.
The transgenic animals did not develop a spontaneous
pancreatitis, although we observed slightly higher base-
line levels of amylase and lipase. Repeated injections of
cerulein led to a more severe pancreatitis in the R122H-
animals. The difference, however, is not pronounced
enough to use these animals as a genetic model system of
pancreatitis. Future attempts to create such a model
should focus on a vector construction that may ensure a
higher expression rate of the cationic trypsinogen in the
pancreata of mice.
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